Erythropoietin inhibits osteoblast function in myelodysplastic syndromes via the canonical Wnt pathway

Ekaterina Balaian, Manja Wobus, Heike Weidner, Ulrike Baschant, Maik Stiehler, Gerhard Ehninger, Martin Bornhäuser, Lorenz C Hofbauer, Martina Rauner, and Uwe Platzbecker

Disclosures: The authors have received grants or honorarium for advisory boards or lectures to the individual or the institution by Novartis (UP, MB, LCH), and Celgene (MB, UP). UP and LCH are supported by a grant within the German Consortium of translational cancer research (DKTK), GE/UP/MB/LCH are supported by the Sonderforschungsbereich (SFB) 655 from the Deutsche Forschungsgemeinschaft (DFG), UP/MR are supported by a grant from the Deutsche Jose Carreras Leukaemie-Stiftung and LCH/MR are supported by a seed grant from the CRTD. The work of EB has been supported by a Gerok rotation position within the SFB 655. All other authors report no conflicts of interest.

Contributions: EB, MR, HW, UB and MW performed and analyzed experiments designed by UP, LCH, MR and EB. EB drafted the manuscript. All the other authors provided patient material, contributed to discussion and to writing the manuscript. * EB and MW contributed equally. # MR and UP contributed equally.